Cytotoxicity, anti-tumor activity, cumulative skin irritation and sensitization study of 5-fluorouracil from a transdermal patch for Dalton's lymphoma ascites cells

Journal of Health Science

Volumn 53, Issue 3, 2007, Pages 275-281

  Chandrashekar, N S ^a   Hiremath, Shobha Rani R ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

5 fluorouracil; Anti tumor activity; Cytotoxicity; Dalton's lymphoma ascites cells; Transdermal patch

Indexed keywords

FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DALTON LYMPHOMA ASCITES CELL; ERYTHEMA; HUMAN; LIFESPAN; MOUSE; NONHUMAN; SKIN IRRITATION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR CELL; TUMOR VOLUME;

MUS;

EID: 34249779548     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.53.275     Document Type: Article

References (21)

1. Banga, A. K. (1995) Transdermal and topical delivery of therapeutic peptides and proteins. In Therapeutics Peptides and Proteins, Technomic Publishing, 4, pp.245-275.
2. Beverley, J., Thomas, and Barrie, F. C. (2004) The transdermal revolution, Drug Dis. Today, 9, 697-703.
3. Guy, R. H. and Hadgraft, J. (1989) Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Marcel Dekker, Inc., New York.
4. Bargman, H. and Hochman, J. (2003) Topical treatment of Bowen's disease with 5-fluorouracil. J. Cutan. Med. Surg., 7, 101-105.
5. Epstein, E. (1985) Fluorouracil paste treatment of thin basal cell carcinomas. Arch. Dermatol., 121, 207-213.
6. Pearlman, D. L., Youngberg, B. and Engelhard, C. (1986) Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis. J. Am. Acad. Dermatol., 15, 1247-1252.
7. Robins, P. and Gupta, A. K. (2002) The use of topical fluorouracil to treat actinic keratosis, Cutis, 70, 4-7.
8. Ansifield, F. J., Schroeder, J. M. and Curreri, A. R. (1962) Five years clinical experience with 5-fluorouracil., J. Am. Med. Assoc., 181, 295-299.
9. McCarron, P. A., Woolfson, A. D., McCafferty, D. F., Price, J. H., Sidhu, H. and Hickey, G. I. (1991) Cytotoxicity of 5-fluorouracil released from a bioadhesive patch into cervical tissue. Int. J. Pharm., 151, 69-74.
10. Diasio, R. B. and Harris, B. E. (1989) Clinical pharmacology of 5-fluorouracil, Clin. Pharmacokinet., 16, 215-237.
11. Murthy, S. N. and Shobha Rani, R. H. (2001) Physical and Chemical Permeation Enhancers in Transdermal Delivery of Terbutaline Sulphate. Pharm Sci. Tech., 2, 1-5.
12. Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J., Yamamura, T. and Hashimoto-Tamakoi, T. (2001) Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res., 61, 1029-1037.
13. Aqil, M., Ali, A., Sultana, Y. and Najmi, A. K. (2004) Fabrication and evaluation of polymeric films for transdermal delivery of pincidal. Pharmazie, 59, 631-635.
14. Su, M. H., Lee, L. H., Addel, G. H., Earl, K. R. and William, H. I. (1994) An application of transdermal antiviral delivery systems to the establishment of a novel animal model approach in the efficacy evaluation for dermatological formulations. Drug. Dev. Ind. Pharm., 20, 685-718.
15. Talwar, G. P. (1974) Handbook of Practical Immunology, National Book trust, New Delhi.
16. Harada, M., Nishitani, H., Koga, K., Miura, I. and Umeno, Y. (1992) Metabolism of Tegafur in rat liver by in vivo 19F magnetic resonance spectroscopy and chromatography. Jpn. J. Cancer Res., 83, 387-391.
17. Kubto, T., Shimosato, Y. and Nagai, K. (1978) Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice, Gann, 69, 299-309.
18. Uchera, N., Baba, H., Nitta, K., Kunimoto, T., Takeuchi, M., Sakai, T. and Tanaka, T. (1985) The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors, Jpn. J. Cancer Res., 76, 1034-1041.
19. Iigo, M., Yamaizumi, Z., Nishimura, S., Hoshi, A. and Clerq, E. (1978) The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2-bromovinyl)-2′- deoxyuridine. Jpn. J. Cancer Res., 78, 409-413.
20. Koenig, H. and Patel, K. (1970) Biochemical basis for fluorouracil neurotoxicity. Arch. Neurol., 23, 155-160.
21. Woolfson, A. D., McCafferty, D. F., McCarron, P. A. and Price, J. H. (1995) A bioadhesive patch cervical drug delivery system for administration of 5-fluorouracil into cervical tissue. J. Controlled Release, 35, 676-681.